Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19
Abstract In the current global emergency due to SARS-CoV-2 outbreak, passive immunotherapy emerges as a promising treatment for COVID-19. Among animal-derived products, equine formulations are still the cornerstone therapy for treating envenomations due to animal bites and stings. Therefore, drawing...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/027fa4cb9478458880985f67c1848752 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:027fa4cb9478458880985f67c1848752 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:027fa4cb9478458880985f67c18487522021-12-02T14:35:47ZDevelopment and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-1910.1038/s41598-021-89242-z2045-2322https://doaj.org/article/027fa4cb9478458880985f67c18487522021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-89242-zhttps://doaj.org/toc/2045-2322Abstract In the current global emergency due to SARS-CoV-2 outbreak, passive immunotherapy emerges as a promising treatment for COVID-19. Among animal-derived products, equine formulations are still the cornerstone therapy for treating envenomations due to animal bites and stings. Therefore, drawing upon decades of experience in manufacturing snake antivenom, we developed and preclinically evaluated two anti-SARS-CoV-2 polyclonal equine formulations as potential alternative therapy for COVID-19. We immunized two groups of horses with either S1 (anti-S1) or a mixture of S1, N, and SEM mosaic (anti-Mix) viral recombinant proteins. Horses reached a maximum anti-viral antibody level at 7 weeks following priming, and showed no major adverse acute or chronic clinical alterations. Two whole-IgG formulations were prepared via hyperimmune plasma precipitation with caprylic acid and then formulated for parenteral use. Both preparations had similar physicochemical and microbiological quality and showed ELISA immunoreactivity towards S1 protein and the receptor binding domain (RBD). The anti-Mix formulation also presented immunoreactivity against N protein. Due to high anti-S1 and anti-RBD antibody content, final products exhibited high in vitro neutralizing capacity of SARS-CoV-2 infection, 80 times higher than a pool of human convalescent plasma. Pre-clinical quality profiles were similar among both products, but clinical efficacy and safety must be tested in clinical trials. The technological strategy we describe here can be adapted by other producers, particularly in low- and middle-income countries.Guillermo LeónMaría HerreraMariángela VargasMauricio ArguedasAndrés SánchezÁlvaro SeguraAarón GómezGabriela SolanoEugenia Corrales-AguilarKenneth RisnerAarthi NarayananCharles BaileyMauren VillaltaAndrés HernándezAdriana SánchezDaniel CorderoDaniela SolanoGina DuránEduardo SeguraMaykel CerdasDeibid UmañaEdwin MoscosoRicardo EstradaJairo GutiérrezMarcos MéndezAna Cecilia CastilloLaura SánchezRonald SánchezJosé María GutiérrezCecilia DíazAlberto AlapeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-15 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Guillermo León María Herrera Mariángela Vargas Mauricio Arguedas Andrés Sánchez Álvaro Segura Aarón Gómez Gabriela Solano Eugenia Corrales-Aguilar Kenneth Risner Aarthi Narayanan Charles Bailey Mauren Villalta Andrés Hernández Adriana Sánchez Daniel Cordero Daniela Solano Gina Durán Eduardo Segura Maykel Cerdas Deibid Umaña Edwin Moscoso Ricardo Estrada Jairo Gutiérrez Marcos Méndez Ana Cecilia Castillo Laura Sánchez Ronald Sánchez José María Gutiérrez Cecilia Díaz Alberto Alape Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19 |
| description |
Abstract In the current global emergency due to SARS-CoV-2 outbreak, passive immunotherapy emerges as a promising treatment for COVID-19. Among animal-derived products, equine formulations are still the cornerstone therapy for treating envenomations due to animal bites and stings. Therefore, drawing upon decades of experience in manufacturing snake antivenom, we developed and preclinically evaluated two anti-SARS-CoV-2 polyclonal equine formulations as potential alternative therapy for COVID-19. We immunized two groups of horses with either S1 (anti-S1) or a mixture of S1, N, and SEM mosaic (anti-Mix) viral recombinant proteins. Horses reached a maximum anti-viral antibody level at 7 weeks following priming, and showed no major adverse acute or chronic clinical alterations. Two whole-IgG formulations were prepared via hyperimmune plasma precipitation with caprylic acid and then formulated for parenteral use. Both preparations had similar physicochemical and microbiological quality and showed ELISA immunoreactivity towards S1 protein and the receptor binding domain (RBD). The anti-Mix formulation also presented immunoreactivity against N protein. Due to high anti-S1 and anti-RBD antibody content, final products exhibited high in vitro neutralizing capacity of SARS-CoV-2 infection, 80 times higher than a pool of human convalescent plasma. Pre-clinical quality profiles were similar among both products, but clinical efficacy and safety must be tested in clinical trials. The technological strategy we describe here can be adapted by other producers, particularly in low- and middle-income countries. |
| format |
article |
| author |
Guillermo León María Herrera Mariángela Vargas Mauricio Arguedas Andrés Sánchez Álvaro Segura Aarón Gómez Gabriela Solano Eugenia Corrales-Aguilar Kenneth Risner Aarthi Narayanan Charles Bailey Mauren Villalta Andrés Hernández Adriana Sánchez Daniel Cordero Daniela Solano Gina Durán Eduardo Segura Maykel Cerdas Deibid Umaña Edwin Moscoso Ricardo Estrada Jairo Gutiérrez Marcos Méndez Ana Cecilia Castillo Laura Sánchez Ronald Sánchez José María Gutiérrez Cecilia Díaz Alberto Alape |
| author_facet |
Guillermo León María Herrera Mariángela Vargas Mauricio Arguedas Andrés Sánchez Álvaro Segura Aarón Gómez Gabriela Solano Eugenia Corrales-Aguilar Kenneth Risner Aarthi Narayanan Charles Bailey Mauren Villalta Andrés Hernández Adriana Sánchez Daniel Cordero Daniela Solano Gina Durán Eduardo Segura Maykel Cerdas Deibid Umaña Edwin Moscoso Ricardo Estrada Jairo Gutiérrez Marcos Méndez Ana Cecilia Castillo Laura Sánchez Ronald Sánchez José María Gutiérrez Cecilia Díaz Alberto Alape |
| author_sort |
Guillermo León |
| title |
Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19 |
| title_short |
Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19 |
| title_full |
Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19 |
| title_fullStr |
Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19 |
| title_full_unstemmed |
Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19 |
| title_sort |
development and characterization of two equine formulations towards sars-cov-2 proteins for the potential treatment of covid-19 |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/027fa4cb9478458880985f67c1848752 |
| work_keys_str_mv |
AT guillermoleon developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT mariaherrera developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT mariangelavargas developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT mauricioarguedas developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT andressanchez developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT alvarosegura developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT aarongomez developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT gabrielasolano developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT eugeniacorralesaguilar developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT kennethrisner developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT aarthinarayanan developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT charlesbailey developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT maurenvillalta developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT andreshernandez developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT adrianasanchez developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT danielcordero developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT danielasolano developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT ginaduran developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT eduardosegura developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT maykelcerdas developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT deibidumana developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT edwinmoscoso developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT ricardoestrada developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT jairogutierrez developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT marcosmendez developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT anaceciliacastillo developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT laurasanchez developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT ronaldsanchez developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT josemariagutierrez developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT ceciliadiaz developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 AT albertoalape developmentandcharacterizationoftwoequineformulationstowardssarscov2proteinsforthepotentialtreatmentofcovid19 |
| _version_ |
1718391050756685824 |